• The Lancet Respiratory Medicine in conversation with

  • 著者： The Lancet Group
  • ポッドキャスト

The Lancet Respiratory Medicine in conversation with

著者： The Lancet Group
無料で聴く

  • サマリー

  • Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

    A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COIVD outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.
    © 2024 The Lancet Group
    続きを読む 一部表示
activate_samplebutton_t1
エピソード
  • Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)

    Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)
    2024/10/25

    Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM).

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    11 分
  • Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

    Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)
    2024/10/25

    Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    10 分
  • Robert Kullberg on empirical antibiotics for Sepsis

    Robert Kullberg on empirical antibiotics for Sepsis
    2024/10/11

    Dr Robert Kullberg joins us to discuss his Viewpoint on empiric antibiotic therapy for sepsis and the importance of reducing unnecessary use of anti-anaerobic antibiotics.

    Read the full article:
    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00257-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanres

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    12 分

あらすじ・解説

Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COIVD outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.
© 2024 The Lancet Group
身体的病い・疾患 衛生・健康的な生活 生物科学
続きを読む 一部表示

The Lancet Respiratory Medicine in conversation withに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。